Acute Exacerbation of Myasthenia Gravis with Topical Imiquimod Use

Abstract

Imiquimod activates the immune system when applied to a local area. We report a patient with a history of well-controlled myasthenia gravis who was prescribed imiquimod for lentigo maligna. Treatment was halted after 2 weeks when the patient reported itching and irritating sensations in his throat, consistent with previous myasthenia exacerbations. The symptoms improved once imiquimod use was discontinued. We advise clinicians to be cautious when prescribing imiquimod to a patient with a history of myasthenia gravis.

Management of keratinocyte carcinoma - Special considerations in the elderly

“…Patients with preexisting autoimmune diseases, such as psoriasis, myasthenia gravis, and HLA B27 spondyloarthropathy, may not be ideal candidates for treatment with IQ in light of reports of disease exacerbations during treatment with IQ, which are thought to be secondary to its immune-stimulating effects (Benson, 2004, Saad et al., 2017, Wu et al., 2004).…”